Aromatherapy and essential oils

Why do buyers get confused by IFRA vs FDA vs EU rules?

Because the same bottle can be sold three different ways.

A 10 mL essential oil can be positioned as:

• a room fragrance input
• a cosmetic or personal-care product
• a wellness product with implied therapeutic use

That is where exposure changes. The oil itself may not change. The claims, instructions, and market placement do.

From a sourcing perspective:

• IFRA documentation is a formula-use signal tied to fragrance applications and concentration limits in specific product categories. It is not a blanket market-clearance document. ([Named third-party] IFRA Standards; IFRA Certificate of Conformity framework)
• FDA-facing exposure can rise when marketing language starts sounding like treatment, prevention, or body-function claims, based on FDA’s product-classification materials and warning-letter patterns. ([Official] FDA, *Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)*; FDA warning-letter context)
• EU exposure can rise when the product’s classification, ingredient disclosure, allergen handling, and product file expectations do not match how the product is being sold. ([Official] Regulation (EC) No 1223/2009; European Commission cosmetics portal; CPNP context)

The mistake is operational. Buyers ask for one certificate when they should be checking alignment across the whole selling stack.

What does an IFRA certificate actually tell you?

It tells you something useful, but narrow.

An IFRA certificate or conformity statement suggests the fragrance composition was assessed against IFRA Standards for stated end-use categories and concentration limits. That can be a strong sourcing signal for home fragrance, personal-care fragrance components, or blended scented products. It does not, on its own, confirm that:

• the supplier used the same formula in production
• the product claims are safe from enforcement risk
• the label fits the destination market
• the product is correctly classified for the market you plan to sell in

A supplier with an IFRA file but no stable formula control is still a risk. A supplier with an IFRA file plus therapeutic marketing copy is a different risk. An IFRA document is not proof of market fit. It is one supporting signal, not a complete market-readiness answer.

Ask one practical question: “Which exact formula, revision date, and end-use category does this IFRA statement cover?” If the answer is vague, the document is weaker than it looks.

When does FDA exposure become a sourcing problem for essential oils?

A practical answer: when the seller brief and the supplier brief stop matching, and the claim set starts to resemble drug-style positioning.

Per FDA’s public product-classification materials and warning-letter examples, claims matter. If an essential oil is marketed with claims that suggest diagnosis, cure, mitigation, treatment, or prevention of disease, or that imply an effect on the structure or function of the body, that can increase FDA-facing exposure. ([Official] FDA, *Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)*; FDA warning-letter context)

For sourcing teams, that means the risk signal often appears before launch:

• the supplier’s packaging mockup includes wellness claims
• the Amazon bullets mention anxiety, pain, sleep disorders, inflammation, or infection
• the insert card makes stronger claims than the outer label
• the same oil is sold as “cosmetic,” “diffuser oil,” and “therapeutic support” across channels

Weak suppliers rarely fail because one document is missing. They often fail because the documents do not agree with each other.

This is a sourcing signal, not regulatory confirmation. Under Agence Octo methodology, if the factory deck, label file, and product page all describe different intended uses, the SKU is unstable before it ships. ([Agence Octo methodology])

What changes when you sell essential oils into the EU?

A practical answer: the main sourcing signal is classification drift between how the product is presented and what documentation the supplier can support.

The EU problem is usually classification drift.

If the product is sold for application to the body, cosmetic-market expectations may become more relevant. If it is sold as a general scented product or room-use item, a different documentation path may apply. If the product presentation mixes categories, buyers create their own risk.

From a sourcing screen, check whether the supplier can keep these elements consistent:

• INCI ingredient naming where relevant ([Official] Regulation (EC) No 1223/2009; European Commission cosmetics portal)
• allergen disclosure expectations where relevant ([Official] Regulation (EC) No 1223/2009; SCCS opinion context)
• safety documentation tied to the actual product type ([Official] Regulation (EC) No 1223/2009; Product Information File context)
• packaging language that matches intended use in the target country ([Agence Octo methodology])

Walk away if the supplier answers category questions with “same as US” or “same as all Europe.” That is not a serious documentation response.

What should buyers ask a supplier before approving an aromatherapy SKU?

Use this practical checklist.

Practical checklist

1. Product-use statement

• Ask: “Is this sold for room diffusion, topical cosmetic use, or another use case?”

1. Formula identity

• Request formula name, revision date, CAS references where relevant, and consistency across COA, SDS, and label files.

1. IFRA support

• Request the IFRA statement tied to the exact formula and intended end-use category.

1. Claims review

• Compare supplier packaging copy, your product page draft, insert cards, and ad copy. The claim set should match the intended category. ([Agence Octo methodology])

1. EU documentation readiness

• Ask what ingredient list, allergen handling, and product-information support the supplier can provide for the target market.

1. Batch consistency

• Confirm whether the oil composition is standardized lot to lot or subject to seasonal variation.

1. Label ownership

• Confirm who controls final copy. Many sourcing problems start when factories recycle old claim language from previous customers.

One concrete mismatch example: the IFRA file names a diffuser-use fragrance formula, while the SDS and product page describe the same SKU for topical roll-on use. That is the kind of document split buyers should pause on immediately.

Diagnostic table

Signal	Usually points to	Why buyers should care
IFRA certificate tied to a named formula and end-use category	Fragrance-use standard support	Useful, but narrow; it does not settle claims, classification, or market-entry fit
Product page or insert uses disease, treatment, or body-function language	Higher FDA-facing claim exposure signal	Marketing language can change how the product is viewed, even if the formula stays the same
EU ingredient naming, allergen, or product-file answers are vague	Higher EU documentation mismatch signal	Supplier may not be prepared to support the product type actually being sold
COA, SDS, label, and IFRA file describe different formulas or uses	General sourcing instability	Document mismatch is often the earliest sign the SKU is not launch-ready

What are the red flags that mean you should pause or walk away?

Red flags

• The supplier sends an IFRA certificate but cannot explain the covered end-use category.
• The formula name on the IFRA file does not match the formula on the SDS or COA.
• The label says “cosmetic use,” while the product page makes therapeutic claims.
• The supplier uses “FDA registered,” “FDA approved,” or similar phrases as a sales shortcut. ([Official] FDA terminology context)
• One SKU is marketed for diffuser use, skin use, and medical-style wellness outcomes at the same time.
• The supplier cannot state whether allergens or ingredient naming requirements differ by market.
• The factory insists one global label works for the US and EU without changes.

Where does Periscope fit?

Periscope helps brands pressure-test product-level market exposure before they commit to a listing, formula, or supplier path. It flags unstable category positioning, claim drift, and document mismatch early, when changes are still cheap. See how it works: Periscope